PRA adds a biotech vet to its board amid an expansion effort

Ocera CEO Linda Grais

PRA Health Sciences ($PRAH) added biotech veteran Linda Grais to its board of directors, broadening its managerial suite as it works to grow around the globe.

Grais is the CEO of Ocera Therapeutics ($OCRX), at work on a Phase II treatment for liver disease. Before taking the helm of Ocera in 2012, she served as a managing partner at biotech investor InterWest. Prior to joining the VC firm, Grais founded and ran SGX Pharmaceuticals until Eli Lilly ($LLY) acquired it in 2008.

Joining PRA's 7-member board, Grais will sit on the audit committee and bring "her extensive experience in the healthcare field as a physician, attorney and biotechnology entrepreneur" to the company's brain trust, CEO Colin Shannon said in a statement.

Meanwhile, PRA is expanding its operation with a particular focus on Pennsylvania, adding about 250 jobs over the next few years as it completes a $4 million new project. The company's latest recruitment effort follows the debut of what PRA calls its Candidate Experience initiative, a multiplatform effort to identify and recruit qualified nurses, study coordinators and healthcare workers who may thrive as clinical research associates.

- read the statement

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.